经典Wnt信号通路抑制剂在多发性骨髓瘤中的研究进展

陈鑫丽; 吴婷婷; 叶宝东; 周郁鸿

doi:10.13201/j.issn.1004-2806.2016.03.024

经典Wnt信号通路抑制剂在多发性骨髓瘤中的研究进展

- 1 浙江中医药大学第一临床医学院(杭州, 310006);
- 2 浙江中医药大学附属第一医院血液科
基金项目:
浙江省高等教育质量工程-中青年学科带头人资助项目(No:GK2011,2012)

详细信息

通讯作者: 叶宝东,E-mail:13588453501@163.com

中图分类号: R733.3

收稿日期: 2015-06-02

Advances in research on inhibitors of canonical Wnt signaling pathways in multiple myeloma

More Information

Corresponding author: YE Baodong, E-mail: 13588453501@163.com

Received Date: 02 June 2015

摘要

- 多发性骨髓瘤 /
- Wnt/β-catenin信号通路 /
- 抑制剂
Abstract: Multiple myeloma(MM)is a disease characterized by clonal proliferation of malignant plasma cells,mainly including osteolytic bone destruction,anemia,renal dysfunction and other symptoms.Canonical Wnt signaling pathway,the most important and fully understood Wnt signaling pathways,has been implicated in the development and progression of many cancers,especially solid tumors.Studies have discovered that abnormal activation of Wnt/β-catenin in MM can promote excessive proliferation of MM cells,which is a potential therapeutic target for MM.In recent years,the inhibitors of canonical Wnt signaling pathways in MM have become a hot spot of research.Here,we review the newest studies on the interaction between MM and inhibitors of canonical Wnt signaling pathways.
- multiple myeloma /
- Wnt/β-catenin signaling pathway /
- inhibitor

HTML全文

参考文献(18)

[1]	Derksen PW,Tjin E,Meijer HP,et al.Illegitimate Wnt signaling promotes proliferation of multiple myeloma cells[J].Proc Natl Acad Sci U S A,2004,101:6122-6127.
[2]	李娟,张殿宝,罗绍凯,等.β-catenin在多发性骨髓瘤中的表达及其临床意义[J].癌症,2007,26(9):1010-1014.
[3]	Cadigan KM,Liu YI.Wnt signaling:complexity at the surface[J].J Cell Sci,2006,119:395-402.
[4]	Gough NR.Focus issue:Wnt and β-catenin signaling in development and disease[J].Sci Signal,2012,5:eg2.
[5]	Amin N,Vincan E.The Wnt signaling pathways and cell adhesion[J].Front Biosci (Landmark Ed),2012,17:784-804.
[6]	李津,钟清玲,刘德伍,等.β-catenin信号分子的生物学功能及其在创伤修复中的研究进展[J].南昌大学学报(医学版),2014,54(7):87-91.
[7]	Kim Y,Gast SM,Endo T,et al.In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma[J].Leuk Res,2012,36:598-600.
[8]	Kim Y,Schmidt M,Endo T,et al.Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model[J].In Vivo,2011,25:887-893.
[9]	Schmeel LC,Schmeel FC,Kim Y,et al.In vitro efficacy of cinnarizine against lymphoma and multiple myeloma[J].Anticancer Res,2015,35:835-841.
[10]	Schmeel LC,Schmeel FC,Kim Y,et al.Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells[J].Anticancer Res,2015,35:1369-1376.
[11]	Schmeel FC,Schmeel LC,Kim Y,et al.Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/beta-catenin pathway[J].Hematol Oncol,2014,32:197-204.
[12]	Schmeel LC,Schmeel FC,Kim Y,et al.Targeting the Wnt/beta-catenin pathway in multiple myeloma[J].Anticancer Res,2013,33:4719-4726.
[13]	Zhang Y,Moschetta M,Huynh D,et al.Pyk2 promotes tumor progression in multiple myeloma[J].Blood,2014,124:2675-2686.
[14]	Park S,Yun E,Hwang IH,et al.Ilimaquinone and ethylsmenoquinone,marine sponge metabolites,suppress the proliferation of multiple myeloma cells by down-regulating the level of β-catenin[J].Mar Drugs,2014,12:3231-3244.
[15]	Zhao JJ,Lin J,Zhu D,et al.miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway[J].Cancer Res,2014,74:1801-1813.
[16]	Zhao JJ,Carrasco RD.Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway:implications for multiple myeloma therapy[J].Cancer Res,2014,74:5351-5358.
[17]	Narayanan BA,Doudican NA,Park J,et al.Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma[J].Anticancer Res,2012,32:4697-4707.
[18]	Yao H,Ashihara E,Strovel JW,et al.AV-65,a novel Wnt/β-catenin signal inhibitor,successfully suppresses progression of multiple myeloma in a mouse model[J].Blood Cancer J,2011,1:e43.